Eli Lilly (LLY) is in advanced discussions to acquire Kelonia Therapeutics for over $2B in a deal that could come as soon as Monday, Lauren Thomas of The Wall Street Journal reports, citing people familiar with the matter. The deal price could include additional consideration if specific milestones are reached by Kelonia, the sources added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- AI Models Split on How Much Upside Is Left in Eli Lilly (LLY)
- The Week That Was, The Week Ahead: Macro and Markets, April 19
- Morning News Wrap-Up, 4/17/26: Today’s Biggest Stock Market Stories!
- Lilly’s New Autoimmune Candidate LY4298445 Moves Through Early Testing
- Eli Lilly’s Oral Orforglipron Study Completion Signals Next Step in Diabetes and Obesity Market Race